Navigation Links
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Date:11/24/2009

SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.

The stock option is intended to be an incentive stock option to the extent permitted by law and has an exercise price per share equal to $7.52, the fair market value on the grant date. The stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to Dr. Klassen's continued service relationship with the Company on each such date. This stock option has a ten year term and is subject to the terms and conditions of the Company's 2007 Equity Incentive Award Plan and the stock option agreement pursuant to which the option is granted.

The stock option was granted as an inducement material to Dr. Klassen's entering into employment with Orexigen Therapeutics in accordance with NASDAQ listing Rule 5635(c)(4).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ... immunotherapies, today announced that it has entered into ... purchase approximately $13.6 million of securities in a ... to such investors an aggregate of 2,469,091 shares ... $5.50 per share. The gross ...
(Date:6/3/2015)... Saudi Arabia , June 3, 2015  Varian Medical Systems ... software for the treatment of cancer, is expanding in the ... strategic operating entity in Saudi Arabia . ... with El Seif Development Group, was officially launched today at ... officer Dow Wilson. "This move represents the ...
(Date:6/3/2015)... , June 3, 2015  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... Lightlake,s partner for treating opioid overdose with intranasal ... New Drug Application (NDA) to the United States ... spray formulation of naloxone, a drug intended to ...
Breaking Medicine Technology:OncoSec Medical Announces $13.6 Million Registered Direct Offering 2OncoSec Medical Announces $13.6 Million Registered Direct Offering 3Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3
... ANGELES, April 28, 2011 This afternoon, at ... Florida, ( http://www.epilepsy.com/etp/aedtrialxi ) Dr. Christopher DeGiorgio, principal ... of a Phase II randomized double-blind clinical trial ... study was conducted at UCLA and the University ...
... DIEGO, April 28, 2011 ResMed Inc. (NYSE: ... quarter ended March 31, 2011.  Revenue for the quarter ended ... a 12% increase on a constant currency basis) over the ... 31, 2011, income from operations was $64.0 million and net ...
Cached Medicine Technology:Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™ 2Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™ 3Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™ 4ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 2ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 3ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 4ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 5ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 6
(Date:6/3/2015)... Tampa, Florida (PRWEB) June 03, 2015 ... mobile friendly website yesterday, to make shopping for health ... The improved website has a fresh look and makes ... for medical centers around you. , Now, when ... prices for radiology and surgical procedures) they can see ...
(Date:6/3/2015)... 03, 2015 The Canton Group, a ... with technology, announced today that Tim Dodge has joined ... joins The Canton Group as it implements ... customer engagements. , Tim is a tech industry veteran ... variety of technology companies. Before joining The Canton Group, ...
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... BC (PRWEB) June 03, 2015 Vancouver ... announced that the firm will now handle personal injury ... Greater Vancouver on the rise, more and more people ... year bus accidents cause needless suffering, serious injury and ... a result of a bus accident in BC you ...
(Date:6/3/2015)... Seattle, WA (PRWEB) June 03, 2015 ... health insurance exchange technology, has announced that CEO Jonathan ... (AHIP) Institute 2015 on June 4, 2015. The ... and digital technologies are disrupting traditional business models in ... new business value. , WHAT: Digital Transformation and ...
Breaking Medicine News(10 mins):Health News:Save On Medical Launches New Mobile-Optimized Website 2Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... pair of new vaccines that not only fight cocaine and ... ,The study was conducted by a team of researchers ... Baylor College of Medicine (BCM). ,As part of ... subjects administered to it. ,Researchers found that study ...
... has shown a decline, thanks to the comprehensive program in ... the 2006 report shows a decline in the smoking ... the past year, smoking decreased among men (from 22.5% to ... declines followed a year-long ad campaign aimed at prompting more ...
... and even dabbled with French, but it was only when ... was established. ,Georgia has an IQ of ... Mensa. ,The youngest daughter of a chief executive and ... on intelligent children as the brightest two-year-old she has ever ...
... GmbH presented the first clinical evidence for the ... for patients suffering from chronic pain at ... Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. Tapentadol, ... its kind, combining two analgesic principles, mu-receptor agonism ...
... university researchers has found a new modified drug for Alzheimers ... trials. ,Millions of people suffer from this ... Ghosh, the Purdue professor who led the creation of the ... be the first disease-modifying therapy. It may be able to ...
... Organization (WHO) based Special Programme for Research and ... new strategy for strengthening and expanding research ... ,The strategy builds on the programmes ... and enhancing research capacity in countries where parasitic ...
Cached Medicine News:Health News:New York Records Decline in Smoking Rate 2Health News:Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 3Health News:Modified Drug Therapy for Alzheimers Disease 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: